Skip to main content

Table 1 Cost inputs

From: Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer

Component

Cost (S$)

Reference

First-line drugs, per vial

 Atezolizumab (840 mg-vial)

4171.56

[f],[g]

 Nab-paclitaxel (100 mg-vial)

667.81

[f]

Subsequent-lines drug regimens, per week

 Cost of subsequent-lines regimens after 1st-line treatment with atezolizumab plus nab-paclitaxel

69.31

[f],[h]

 Cost of subsequent-lines regimens after 1st-line treatment with nab-paclitaxel

90.59

[f],[h]

Intravenous drug administration, per administrationa

 Drug preparation fee by pharmacy

52.80

[f]

 Facility fee/chair time

272.20

[f]

Disease monitoring and management, per session

 Doctor’s clinic consultation b

74.57

[f]

 Computed tomography (CT) scan c

940.00

[f]

 Liver function test b

71.30

[f]

 Renal panel b

62.80

 

 Full blood count d

26.46

[f]

 Thyroid function test (for patients receiving atezolizumab) b

226.28

[f]

Palliative care, per month

 Cost of palliative care e

3210.90

[i]

  1. aThe frequencies of administration of first-line drugs (atezolizumab and nab-paclitaxel) were in line with the IMpassion130 clinical trial, while that of subsequent-lines drugs were informed by licensed dosing regimens or NCCN clinical guideline
  2. bPerformed every 4 weeks for patients receiving anti-cancer therapies, according to local practice
  3. cCT scan was performed every 10 weeks for patients receiving anti-cancer therapies (CT scans are typically done every 8–12 weeks in local practice)
  4. dTest was performed weekly during treatment with nab-paclitaxel. For patients on other therapies, the test was performed every 4 weeks, according to local practice
  5. eIt was assumed that palliative care was provided for 1 month before death
  6. fThe costs of drugs, drug administration or disease management were estimated from the average costs to patients at public healthcare institutions in Singapore (2018)
  7. gThe cost of atezolizumab 840 mg-vial was extrapolated from that of the 1200 mg-vial, assuming linear pricing
  8. hSubsequent-lines drugs provided to > 5% of patients in at least one of the two arms within the IMpassion130 trial were considered. Drug costs were calculated based on the dosing regimens recommended by package inserts or NCCN clinical guideline and an average BSA of 1.6m2. The average cost was weighted according to the proportion of use of each drug reported in the trial
  9. iThe average cost of palliative care (weighted according to the proportion of patients receiving inpatient hospice care or home-based care) was obtained from one hospice centre in Singapore
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us